Skip to main content
Clinical Trials/NCT01991444
NCT01991444
Completed
Not Applicable

Registry Study to Evaluate the Predictive Value of a Comprehensive Geriatric Assessment With Regard to the Outcome of a Transcatheter Aortic Valve Implantation.

Institut für Pharmakologie und Präventive Medizin3 sites in 3 countries72 target enrollmentFebruary 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Valve Stenosis
Sponsor
Institut für Pharmakologie und Präventive Medizin
Enrollment
72
Locations
3
Primary Endpoint
Comprehensive geriatric assessment
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Registry study to evaluate the predictive value of a comprehensive geriatric assessment with regard to the outcome of a transcatheter aortic valve Implantation.

It will be evaluated which parts of the comprehensive geriatric assessment (CGA) are best suited to predict the therapeutic success of a heart valve Implantation in elderly ( > 80 years) Patient. Possible participants are all Patient of 80 years or above for whom the implantation of a Edwards Sapien XT aortic valve is planned

Detailed Description

Transcatheter Aortic Valve Implantation Registry with Comprehensive Geriatric Assessment

Registry
clinicaltrials.gov
Start Date
February 2014
End Date
February 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Institut für Pharmakologie und Präventive Medizin
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Scheduled TAVI using Edwards SAPIEN XT Transcatheter Heart Valve
  • Compliance with the indications of the instructions for use
  • Age of at least 80 years
  • Written informed consent

Exclusion Criteria

  • Presence of contraindications as to the Instructions for Use
  • No possibility for a follow-up

Outcomes

Primary Outcomes

Comprehensive geriatric assessment

Time Frame: Baseline and 3 months

Demonstrate CGA changes within 3 months after TAVI The CGA is an array of several different assessments with regard to frailty, comorbidities, administrative data (Silver code), Quality of life etc. Every Patient will undergo a CGA at baseline and 3 months after TAVI. Data will be analyzed to determine changes in CGA results.

Secondary Outcomes

  • Score development(after 3 months)
  • predictive Value of CGA Tavi(baseline)

Study Sites (3)

Loading locations...

Similar Trials